Enterolactone restricts the proliferation of the LNCaP human prostate cancer cell line in vitro

• Published in: Molecular nutrition & food research 2008-05, Vol.52 (5), p.567-580
• Main Authors: McCann, Mark J, Gill, Chris I.R, Linton, Trevor, Berrar, D, McGlynn, Hugh, Rowland, Ian R
• Format: Article
• Language: English
• Subjects: 4-Butyrolactone - analogs & derivatives; 4-Butyrolactone - pharmacology; Apoptosis; Biological and medical sciences; Cell Division - drug effects; Cell Line, Tumor; Cell Survival - drug effects; Enterolactone; Food industries; Fundamental and applied biological sciences. Psychology; Gene expression; Humans; Lignans - pharmacology; LNCaP; Male; Mitochondria - drug effects; Mitochondria - pathology; Phytoestrogens - pharmacology; Polymerase Chain Reaction; Proliferation; Prostate-Specific Antigen - drug effects; Prostate-Specific Antigen - genetics; Prostatic Neoplasms - pathology
• ISSN: 1613-4125; 1613-4133
• DOI: 10.1002/mnfr.200700052

Ecological data suggest a long-term diet high in plant material rich in biologically active compounds, such as the lignans, can significantly influence the development of prostate cancer over the lifetime of an individual. The capacity of a pure mammalian lignan, enterolactone (ENL), to influence the proliferation of the LNCaP human prostate cancer cell line was investigated as a function of cell density, metabolic activity, expression and secretion of prostate specific antigen (PSA), cell cycle profile, and the expression of genes involved in development and progression of prostate cancer. Treatment with a subcytotoxic concentration of ENL (60 μM for 72 h) was found to reduce: cell density (57.5%, SD 7.23, p < 0.001), metabolic activity (55%, SD 0.03, p < 0.001), secretion of PSA (48.50% SD 4.74, p = 0.05) and induce apoptosis (8.33-fold SD 0.04, p = 0.001) compared to untreated cells. Cotreatment with 10 μM etoposide was found to increase apoptosis by 50.17% (SD 0.02, p < 0.001). Additionally, several key genes (e. g. MCMs, survivin and CDKs) were beneficially regulated by ENL treatment (p < 0.05). The data suggest that the antiproliferative activity of ENL is a consequence of altered expression of cell cycle associated genes and provides novel molecular evidence for the antiproliferative properties of a pure lignan in prostate cancer.